Greenwich LifeSciences, Inc 8-K, filed Dec 9, 2022
Greenwich LifeSciences, Inc. (GLSI)
About this 8-K
Greenwich LifeSciences, Inc filed this 8-K on December 9, 2022.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I. R. S. Employer Identification No.) |
(Address of principal executive offices, including ZIP code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders
On December 9, 2022, Greenwich LifeSciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 9,755,196 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on October 19, 2022 are as follows:
Proposal 1. All of the five (5) nominees for director were elected to serve until the 2023 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five (5) directors was as follows:
| Directors | For | Against | Abstain | Broker Non Vote | ||||||||||||
| David McWilliams | 8,452,115 | 0 | 484,781 | 818,300 | ||||||||||||
| Snehal S. Patel | 8,567,603 | 0 | 369,293 | 818,300 | ||||||||||||
| Eric Rothe | 8,526,477 | 0 | 410,419 | 818,300 | ||||||||||||
| F. Joseph Daugherty, M.D. | 8,532,215 | 0 | 404,681 | 818,300 | ||||||||||||
| Kenneth Hallock | 8,561,615 | 0 | 375,281 | 818,300 | ||||||||||||
Proposal 2. The appointment of Malone Bailey, LLP as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2022 was ratified and approved by the stockholders by the votes set forth in the table below:
| For | Against | Abstain | Broker Non Vote | |||||||||||
| 9,733,708 | 15,043 | 6,444 | 0 | |||||||||||
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Greenwich LifeSciences, Inc. | ||
| Date: December 9, 2022 | By: | /s/ Snehal Patel |
| Snehal Patel | ||
| Chief Executive Officer | ||
| -3- |